Neurology

PhaseV to Present Transformative Use of AI for Clinical Development at Upcoming Events

Presentations to Highlight the Power of Advanced Machine Learning for Enhancing Trial Design, Execution and Analysis BOSTON, April 8, 2025…

8 months ago

Brainomix Advances Stroke Care with Landmark FDA Clearance

Brainomix 360 unlocks expert-level insights from universally available non-contrast CT scans, helping stroke networks expand access to life-changing treatmentsOXFORD, England…

8 months ago

Quibim Announces New Board of Directors To Promote Growth And Strategic Expansion

NEW YORK & VALENCIA, Spain & CAMBRIDGE, England--(BUSINESS WIRE)--#AIinHealthcare--Quibim, the global pioneer in imaging biomarkers for precision medicine, is pleased…

9 months ago

BlackDoctor.org Announces Inductees in First Hall of Fame, BDOs Highest Distinction, Recognizing Lifetime Achievements in the US Healthcare Industry

CHICAGO, April 4, 2025 /PRNewswire/ -- In a historic moment, BlackDoctor.org (BDO) inducts its first class into the inaugural TBH…

9 months ago

Xenon to Showcase Long-Term 36-Month Azetukalner Data at AAN 2025

Three epilepsy posters to be presented in scientific sessions at the American Academy of Neurology meetingLong-term 36-month data from the…

9 months ago

Cadwell Unveils Synchronized EMG and Ultrasound, Q-Mode and Other Innovations in Latest Sierra Software Release

KENNEWICK, Wash., April 3, 2025 /PRNewswire/ -- Cadwell Industries, Inc., a global leader in neurodiagnostic, neuromonitoring and sleep solutions, launched its…

9 months ago

SPARK NS Selects Eight Projects to Receive Aggregate Funding of Up to $16 Million to Advance Academic Discoveries in Parkinson’s Disease from the Lab to the Clinic

Academic research teams of selected projects participate in a translational research program that eliminates barriers that prevent promising discoveries from…

9 months ago

NeuroPace Announces Upcoming Oral Presentation of Data from the Long-Term Post-Approval Study of the RNS System at the 2025 AAN Annual Meeting

Three-year data from NeuroPace’s Post-Approval Study of the RNS® System in drug-resistant focal epilepsy to be shared in oral presentationMOUNTAIN…

9 months ago

Alterity Therapeutics to Deliver an Oral Presentation of the Positive ATH434 Phase 2 Trial Results at the American Academy of Neurology Annual Meeting

MELBOURNE, Australia and SAN FRANCISCO, April 03, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the…

9 months ago